

1 Musiliu A. Oyenike<sup>1,2</sup>, Frederick O. Akinbo<sup>2\*</sup>, Kamoru A. Adedokun<sup>3\*</sup>, Hammed O. Ojokuku<sup>4</sup>,  
2 Sikiru O. Imodoye<sup>5</sup>, Lukman A. Yunus<sup>6</sup>, Ismaila A. Lasisi<sup>7</sup>, Abdulahi A. Jimoh<sup>8</sup>

3 <sup>1</sup>Department of Medical Laboratory Science, College of Health Science, Ladoke Akintola University of  
4 Technology, Ogbomoso Oyo state, Nigeria; <https://orcid.org/0000-0002-2160-1433>.

5 <sup>2</sup>Department of Medical Laboratory Science, University of Benin, Benin City, Edo State Nigeria;  
6 <https://orcid.org/0000-0002-5887-753X>.

7 <sup>3</sup>Department of Oral Pathology, DUH, King Saud University Medical City, Riyadh, Saudi Arabia;  
8 <https://orcid.org/0000-0001-9833-3011>.

9 <sup>4</sup>Department of Medical Laboratory, Lagos State Health Service Commission, Lagos State, Nigeria;

10 <sup>5</sup>Department of Biological Sciences, University of the Sciences, Philadelphia, USA; <sup>6</sup>Department of  
11 Histopathology and Morbid Anatomy Uniosun Teaching Hospital, Osogbo, Osun State, Nigeria;

12 <sup>7</sup>Health Center Department, Osun state Polytechnic, Iree. Osun state;

13 <sup>8</sup>Department of Chemical Pathology, School of Medical Laboratory Science, Usmanu Danfodiyo  
14 University, Sokoto, Nigeria;

15 \*Corresponding authors:

16 E-mail: [fgbengang@yahoo.com](mailto:fgbengang@yahoo.com); [adeolokun@yahoo.com](mailto:adeolokun@yahoo.com)

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35 **Synchronicity of P53 Mutation and Multiple High-Risk HPV Genotypes, and the Risk of**  
36 **Cervical Cancer among Women in Osogbo, Nigeria**

37

38

**Abstract**

39 **Background:** In low-and middle-income countries, high burden of cervical cancer is associated  
40 with human papillomavirus (HPV) due to poor screening and diagnostic methods at early stage.  
41 Reports showed that there are discrepancies in data correlating HPV-infection with development  
42 of cervical cancer while the functional roles of *P53* oncogenic mutation are controversial.  
43 Furthermore, the molecular pathogenesis of multiple HPV-genotypes remains an open question.  
44 Thus, advancing investigations on HPV-associated cervical abnormalities would add to early  
45 diagnostic precision.

46 **Methods:** Two hundred (n=200) cervical samples were collected from apparently healthy, active  
47 adult women following an ethical approval. Laboratory analyses were conducted through  
48 cytological assessment and histochemistry screening using the Papanicolaou smear. PCR  
49 methods were used to characterize HPV-DNA genotypes and *P53* gene mutations. Positive  
50 cervical dysplasia cases were matched with HPV-DNA, and the HPV-genotypes were used to  
51 evaluate the prevalence of various HPV-subtypes and the risk of cervical cancer.

52 **Results:** Twenty-six (n=26) cervical dysplasia and fifty-one (n=51) HPV+ were identified  
53 comprising single and multiple genotypes. While nine cases (n=9) showed *p53* gene mutation  
54 with concurrent multiple high-risk HPV (hrHPV) genotypes, none of the single hrHPV  
55 genotypes had *p53* mutation. More so, individuals with coexisting *p53* mutation and multiple  
56 hrHPV-genotypes already manifesting cervical dysplasia were 22.2% of the group, while 77.8%  
57 had normal cervical architecture, the fate of whom was unknown during investigation. There was  
58 a higher cervical dysplasia among those with HPV oncogenes; there were connections between  
59 the HPV positivity with some genotypes (hrHPV16,18,31 and 33, respectively) and *p53*  
60 mutation.

61 **Conclusion:** *P53* gene mutation was independent of HPV-associated cervical abnormalities in  
62 single hrHPV-genotype, though other mechanistic drivers attributed to *p53* dysfunction by E6  
63 and E7 remain plausible. On the other hand, infection with multiple hrHPVs showed a  
64 concomitant predominance with the *P53* mutation, implying a potential interplay and an  
65 increased risk of cervical cancer.

66 **Keywords:** Cervical cancer; gene polymorphism; human papillomavirus; HPV-genotypes; *P53*  
67 mutation; Pap's smear; Osogbo metropolis

68

69

## 70 **Background**

71 According to a recent GLOBOCAN database, out of the infection-attributable cancer cases  
72 diagnosed worldwide, human papillomaviruses (HPV) caused about 31.1%, second to  
73 *Helicobacter pylori* (36.3%) [1]. HPV is the most common cause of cervical cancer, especially  
74 by high-risk HPV (hrHPV) genotypes such as HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,  
75 59, 66, and 68, according to the World Health Organization (WHO); [2]. Also, hrHPVs are the  
76 most important risk factors present in 99.7% of the invasive cervical cancer, particularly among  
77 the young women [3]. In Nigeria, cervical cancer is one of the top five malignancies commonly  
78 diagnosed (excluding non-melanoma skin cancer). According to a recent global incidence  
79 analysis, cervical cancer accounts for 16.4% (equal to 12, 075 new cases) of the total 73, 417  
80 new cancer cases among the female population, which include cancers of the breast, ovary,  
81 colorectum, non-Hodgkin lymphoma, and several others in Nigeria [4]. According to this report,  
82 Nigeria is one of the leading countries currently dealing with a high cervical cancer rate caused  
83 by HPV infection in females.

84 Although tremendous progress has been made in understanding HPV's life cycle and role in the  
85 development of cervical cancer, the molecular events remain poorly understood and have been  
86 the subject of debate for mortality disparities around the world. A number of other factors, either  
87 directly or indirectly related to HPV infection, are associated with the development of cervical  
88 cancer in developing countries. These include a lack of knowledge, insufficient screening  
89 programs, inaccurate diagnosis, ineffective treatment methods, and increased exposure to risk  
90 factors. Generally, poor hygiene, smoking, oral contraceptive use, diethylstilbestrol (DES)  
91 exposure, and genetic predisposition have all been identified as common causes of cervical

92 cancer in economically disadvantaged women [5]. From the knowledge of pathogenesis, cervical  
93 cancer develops after a long-term infection with the hrHPV, often after decades. Also, for  
94 cervical precancerous lesions to progress to invasive carcinoma, genetic and epigenetic  
95 alterations in host cell genes are involved.

96 Established knowledge shows that in many cancer cases a genetic predisposition is caused by  
97 mutations in tumor suppressor genes. P53 and retinoblastoma (Rb) are the two well-  
98 characterized tumor-suppressor genes, which encode proteins that repair damaged DNA. In  
99 cervical cancer patients, alterations in the Rb and p53 have been repeatedly implicated [6-8].  
100 More importantly, P53 is known as the key player in the etiology of cervical cancer from a  
101 mechanistic standpoint. Unfortunately, several molecular interactions have been shown to  
102 suppress p53 activities, leading to cervical carcinogenesis [9]. P53 mutations, E6 and E7  
103 malfunction, p53 degradation, overexpression of major p53 negative regulators like murine  
104 double minute 2 (MDM2) or MDM4, epigenetic dysregulation, and even alterations in TP53  
105 mRNA splicing are just a few examples [6, 8]. Despite the fact that the tumor suppressor p53 is  
106 mutated in 50 percent of all human cancers [7] a simultaneous occurrence of p53 mutation and  
107 HPV infection, as well as a possible interaction that appears to be significantly related, remains  
108 doubtful. According to an earlier report, although p53 mutations are uncommon, HPV has been  
109 implicated in more than 90% of cervical malignancies [10]. To gain more insights, several  
110 studies further investigated the frequency of p53 mutations in cervix squamous cell carcinoma  
111 and adenocarcinoma, with varied outcomes. One of these studies examines the p53 mutation  
112 spectrum in cervical cancer cases from various geographical regions [11]. The findings show that  
113 the proportion of adenocarcinoma with mutated p53 ranged from 4% in North America to 19%

114 in Asia, affecting six hot-spot codons of the gene, with three codons (175, 248 and 273)  
115 predominating in both types of the cancer [11].

116 A recent study of p53 gene mutation from African origin discovered various p53 gene mutations  
117 [12]. The study further explains that diverse environmental exposures and their vulnerabilities  
118 could be accountable for the divergence in polymorphism variants with connection to cervical  
119 oncogenesis. Other studies show that p53 is commonly inactivated by a variety of mechanisms,  
120 particularly in cancers with low p53 mutation rates, which could be a factor in HPV-positive  
121 cervical cancer, where p53 is ubiquitin-targeted for destruction by the E6 protein [13]. However,  
122 p53 mutation has been postulated as a possible unique pathway for oncogenesis in HPV-negative  
123 cervical cancer. More than one hrHPV genotype (multiple genotypes) are present in some  
124 individuals who are at a higher risk of cervical cancer, perhaps, causing synergistic effects and  
125 accelerating cervical architectural change, which may eventually leads to and hasten cervical  
126 cancer development.

127 Unfortunately, based on the studies above, the possible interaction of hrHPV genotypes with the  
128 concurrent p53 mutation could be unimaginable. Currently, the majority of available data focuses  
129 on either single hrHPV genotypes as a risk factor for cervical dysplasia or p53 mutation as a  
130 molecular driver in HPV-negative cervical cancer. More research is needed to better understand  
131 the molecular interplay of different hrHPV genotypes that orchestrate cervical abnormalities,  
132 especially in high-risk black populations. As a result, the goal of this study was to better  
133 understand the etiopathogenesis of cervical abnormalities in adult women in Osogbo metropolis,  
134 southwestern Nigeria, in relation to p53 mutation and hrHPV genotypes, in order to improve  
135 early diagnostic precision and reduce the risk of cervical cancer development.

136

137

138

## 139 **MATERIAS AND METHOD**

### 140 **Study Area**

141 This study was conducted at women attending the Obstetrics and Gynaecology clinics Ladoke  
142 Akintola University Teaching Hospital (LTH), Osogbo Central Hospital, and NasiruLahi-li-  
143 Fatihi Society of Nigeria (NASFAT), Health Center Osogbo, Osun State, southwestern Nigeria.  
144 Osogbo is a city in Nigeria with a population of 499,999 people and a land area of 2875 km<sup>2</sup>. It  
145 shares borders with Ikirun, Ilesa, Ede, Egbedore, Ibokun and Iragbiji [14]. The majority of the  
146 residents are Yoruba speakers and small-scale traders. As the capital of Osun State, Osogbo is  
147 the seat of government. Kwara State to the north, Oyo State to the west, Ogun State to the south,  
148 and Ondo and Ekiti States to the east, all share boundaries with Osun State.

### 149 **Study Population**

150 A total of 200 cervical smears were collected from women in various parts of the city (as  
151 mentioned above). Participants ranged in age from 20 to 65 years old. Prior to the collection of  
152 the specimens, each participant was given a standardized questionnaire that asked about their  
153 bio-data and socio-demographic factors. Before collecting the specimen, each participant gave  
154 their written consent.

### 155 **Inclusion Criteria**

156 All adult women between 20 years and above that consented to participate were recruited in this  
157 study.

### 158 **Exclusion Criteria**

159 Participants that have other chronic diseases, those that refused consent and individuals less than  
160 20 years were excluded from this study.

161

## 162 **Sample Size**

163 The sample size (N) was determined using the formula  $N = Z^2 P (1-p) / d^2$

164 Where; N = Minimum Sample Size

165 Z = confidence interval (1.96) from statistical table

166 P = prevalence rate (14.7%) [15].

167 d = desired level of significance taken as 0.05

168

169  $N = Z^2 P (1-p) / d^2$

170  $N = (1.96)^2 \times 0.147 (1 - 0.147) / 0.05^2$

171  $N = 3.8416 \times 0.147 \times 0.853 / 0.0025$

172  $N = 3.8416 \times 0.125391 / 0.0025$

173  $N = 0.4817020656 / 0.0025$

174  $N = 192.68 = 193$  participants.

175 A minimum of 200 participants were recruited.

176

## 177 **Ethical Clearance**

178 The protocol for this study was approved by the Osun State Health Research Ethics Committee  
179 (OSHREC) of the Ministry of Health, Osogbo, Osun State with reference number  
180 OSHREC/PRS/569T/158, 2019.

## 181 **Specimen Collection**

182 Kavatkar et al. previously described a method for collecting cervical smears, which was used in  
183 this study [16]. Following sterile speculum dilatation of the vaginal wall, a cytobrush was  
184 introduced into the endocervical canal, turned clockwise, extracted, and placed in fixative. The  
185 mixture was allowed to sit for 30 minutes before being labeled [17]. It was then decanted and  
186 diluted with cellular solution after being placed into a spin tube and centrifuged at 1500rpm for  
187 60 seconds. A 50ul portion of the diluted liquid was utilized to make a smear with a brush, while  
188 the rest was kept in the refrigerator for molecular analysis. The smear slides were air-dried for 3  
189 to 5 minutes before being stained with Haematoxylin and Eosin. For DNA extractions, 500ul of  
190 refrigerated samples were placed in Eppendorf tubes, with the remaining samples being  
191 preserved in the refrigerator for future use [18].

## 192 **Processing of Specimen**

### 193 *Staining of Cervical Smear*

194 Following the fixing, the Papanicolaou staining technique was used to stain the smear. The  
195 smears were immersed in water for 4 minutes, stained with Harris haematoxylin, rinsed in water,  
196 differentiated in 0.5 % acid alcohol for 10 seconds, rinsed in water again, and blued in running  
197 tap water for 10 minutes. The stained smears were dipped in two changes of 90 % alcohol before  
198 staining in Orange G6 dye for 2 minutes. The stained smears were then rinsed three times with  
199 95 % alcohol before being counterstained with Eosin Azure 50 solution for 4 minutes.  
200 The smears were rinsed in two changes of 95 % alcohol, dehydrated in two changes of absolute  
201 ethanol, cleared in xylene, and mounted in DPX [19]. The stained slides were reported according  
202 to the Bethesda System [20]. The reports were made as follow: normal without altered cells;  
203 atypical squamous cells of undetermined significance (ASC-US); atypical squamous cells –  
204 cannot exclude HSIL (ASC-H); low-grade squamous intraepithelial lesion (LSIL); and high-



205 grade squamous intraepithelial lesion (HSIL). The cases with abnormal cytological diagnoses of  
206 HSIL and LSIL (Positives) were confirmed.

207

208

### 209 ***PCR Determination Method for HPV Gene***

210 Following the manufacturer's instructions, DNA was extracted using a Jena extraction kit. To  
211 ensure that enough DNA had been extracted, the extracted DNA was run on a 1% agarose gel.

212 The samples were tested for the presence of HPV DNA using the GP5+/6+ primers MY09  
213 (5'CGTCCM AARGGAWACTGATC-3') and MY11 (5'-GCMCAG GGWCATAAYAATGG-  
214 3'), which target the conserved sequences in the HPV L1 region and may identify a variety of  
215 low and high risk mucosal HPVs. The samples were tested for the presence of HPV (the most  
216 commonly identified HR-HPVs in cervical cancer) using type specific primers [21].

217

### 218 **DNA Extraction**

219 The full DNA extractions were carried out with the Jena extraction kit, following the  
220 manufacturer's instructions with only minor modifications. The sample tubes were thawed, then  
221 vortexed and centrifuged for 1 minute each after adding 1000ul phosphate buffer. 300ul of lysate  
222 was pipetted into another tube, along with 2ul of proteinase K, vortexed for 15 seconds, and  
223 incubated for 1 hour at 55°C. 100ul protein precipitation was added, and the mixture was  
224 centrifuged for 1 minute. The supernatant was stirred 50 times and vortexed for 20 seconds after  
225 addition of 300ul of isopropanol. The supernatant was then discarded after centrifugation at  
226 15,000 for 1 minute. 500ul of washing buffer was added to the tube, which was then inverted  
227 multiple times and air-dried at room temperature. Then, 50ul of hydrated solution was added for  
228 additional PCR amplification and other analyses [21, 22].

229

## 230 **Polymerase Chain Reactions for HPV and P53 Gene Mutation Analyses**

231 In a 9600 thermocycler, polymerase chain reactions (PCRs) were performed. The PCR  
232 temperature cycles and duration for the reactions occurred as follow; denaturation at 94°C for 5  
233 minutes, 94°C for 30 seconds, annealing at 56°C for 30 seconds, and extension at 72°C for 45  
234 seconds. Each PCR reaction was preceded by a 5-minute denaturation step at 95°C, followed by  
235 a 5-minute extension step at 72°C. Depending on the sample volume reactions, the total number  
236 of PCR amplification cycles ranged from 30 to 40. 50ul final volume containing 50 mM KCl, 10  
237 mM Tris-HCl pH 8.3, 200 M concentration of each dNTP, 1.5 mM MgCl<sub>2</sub>, 1ul of thermostable  
238 DNA polymerase (AmpliTaq DNA polymerase), and 15 pmol of each primer, was used. 2ul of  
239 the PCR product served as template for the nested PCRs. 10ul of the amplification products was  
240 analyzed by electrophoresis on 2% agarose gels and safragreen was used to stain [22].

241

## 242 **Detection of HPV-DNA Genotypes**

243 To achieve precise HPV infection typing, type-specific nested multiplex Exon 6 primers were  
244 used. These primers were chosen from sequence alignments of the E6/E7 genes, with the goal of  
245 detecting sequence variations even among closely related genotypes. Nested primers were  
246 arranged in multiplex PCR primer cocktails to reduce the number of nested PCRs required to  
247 discriminate between a wide range of different HPV genotypes. The high-risk genotypes 16, 18,  
248 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, and 68 were identified using established primers. The  
249 primers were mixed into cocktails with four to five different primer pairs in each. The size of the  
250 nested PCR amplification product was determined by gel electrophoresis of molecular sizes 457,  
251 322, 263, 398, 358, 280.151, 223, 229, 181, 274, 172, and 333 base pairs (Bp), respectively, to  
252 identify each HPV type present [22].

253

## 254 **Determination of HPV-DNA Genotyping Using PCR**

255 For Taq amplification in the thermocycler 9600, a total reaction volume of 25 mL was prepared  
256 with 50 ng genomic DNA, 20 pmol of each primer, 200 μM of each dNTPs mixed with Taq  
257 buffer (10 mM, 384 Tris-HCl pH 8.3, 50 mM KCl), 3.0 mM MgCl<sub>2</sub>, and 3 units of Taq  
258 polymerase (New England, Biolabs). To guarantee complete extension of all PCR products,  
259 cycling settings were 3 minutes at 94°C for denaturation, 1 minute at 60 °C for annealing, and 7  
260 minutes at 72 °C for final extension at 35 cycles. Gel electrophoresis was used to determine the  
261 PCR amplification product, which was done with a negative control and a 100 base pair  
262 molecular ladder.

263

## 264 **Detection of P53 Exon 6 Mutation**

265 The P53 gene status, were evaluated after the DNA genotyping using the multiplex PCR method  
266 Mutations in the p53 gene occur most frequently within exons 5–8, which is the highly  
267 conserved DNA binding domain region [22]. Studies on p53 that included all exons have  
268 suggested that mutations outside exons 5–8 are rare in tumors [23]. The mutations of the p53  
269 gene was verified by PCR-Single Strand Conformational Polymorphism (PCR-SSCP), which  
270 detects molecular changes in single-stranded DNA that cause changes in electrophoretic mobility  
271 through the following primers:

272 Exon, 6 (5'-TGGTTGCCAGGGTCCCCAG-3') / (5'TGGAGGGCCACTGACAACCA-3'),

273 223 bp [22].

274

## 275 **Determination of p53 Gene Mutation**

276 The p53 gene mutation was determined using 20 μl of DNA extracted lysates, a 9600  
277 thermocycler, 10 mM Tris-HCl (pH 8.3), 2.0 mM MgCl<sub>2</sub>, 50 mM KCl, 0.1% Tween-20, 0.2 mM

278 dNTP, 10 pM of each primer, and 2 units of AmpliTaq Gold polymerase (Perkin-Elmer). PCR  
279 reactions were denatured at 94°C for 30 seconds, annealed at 55°C for 30 seconds, and extended  
280 at 72°C for 30 seconds. Each PCR reaction was followed by a 7-minute extension at 72°C after a  
281 5-minute denaturation at 95°C. Depending on the sample DNA, the total number of PCR  
282 amplification cycles ranged from 35 to 40. The size of the P53 gene amplification products size  
283 were determined using a gel electrophoresis equipment to identify electrophoresis bands.  
284 Specific forward and reverse primers selected for PCR reaction of p53 gene regulation are as  
285 follow:

286 p53

287 F = 50 -TGA AGT CTC ATG GAA GCC AGC-30

288 R = 50 -GCT CTTT TTC ACC CAT CTA CAG-30

## 289 **RESULTS**

291 Out of the 200 women who took part in the study, 51 (25.5 percent) had HPV infection (Table  
292 1). HPV-16, 18, 31, 33, 39, 66, and 68 were the HPV types discovered in this investigation, with  
293 HPV-31 having the highest frequency (Figs 1 - 3). In addition, the people aged 60 and up had the  
294 highest prevalence. Furthermore, participants who were traders had the highest risk of HPV  
295 infection, with the majority of them holding an elementary school certificate. Education and  
296 menopausal status, in particular, were found to have considerable connections with the risk of  
297 HPV infection. Religion affiliation, coital frequency, vaginal discharge, and menstruation pain,  
298 on the other hand, showed no link to HPV infection. Although the majority of the participants  
299 had normal cervical architecture, the proportion of HPV-infected people among those with  
300 abnormal cytology (dysplasia) was higher than in the normal group. Aside from that, multiple

301 hrHPV-infected participants were seen. hrHPV 16 + 31 genotypes were the most predominant  
 302 among them.

303

304

305 **Table 1: Sociodemographic Characteristics of Study Participants**

Relationship between age distribution and HPV infection		
Age	No. Infected/No Tested (%)	P-value
20 – 29	5/27 (18.5)	0.846
30 – 39	11/41(26.8)	
40 – 49	9/59(15.3)	
50 – 59	19/55(34.5)	
60 and above	7/18(38.9)	
Relationship between occupation and HPV		
Occupation	No. Infected/No Tested (%)	P-value
Trader	16/75 (21.3)	0.417
Student	9/46 (19.6)	
Civil servant	19/54 (35.2)	
House wife	6/25 (24.0)	
Association between educational status and HPV infection		
Educational Status	No. Infected/No Tested (%)	P-value
None	15/73 (20.5)	< 0.001
Primary	7/19 (36.8)	
Secondary	12/51 (23.5)	

Tertiary	17/57 (29.8)	
<b>Religion and HPV infection</b>		
Religion	No. Infected/No Tested (%)	P-value
Muslim	31/129 (24.03)	0.578
Christians	20/71 (28.2)	
<b>Relationship between menopausal status and HPV</b>		
Menopause	No. Infected/No Tested (%)	P-value
No	29/142 (20.4)	0.012
Yes	22/58 (37.9)	
<b>Relationship between coitus frequency and HPV</b>		
Coitus	No. Infected/No Tested (%)	P-value
None	9/40 (22.5)	0.619
Weekly	8/45 (17.8)	
Monthly	34/114 (29.8)	
<b>Association between abnormal vaginal discharge and HPV</b>		
discharge	No. Infected/No Tested (%)	P-value
No	36/138 (26.1)	0.249
Yes	15/62 (24.2)	
<b>Association between menstrual pain and HPV</b>		
menstrual pain	No. Infected/No Tested (%)	P-value
No	43/166 (25.9)	0.877
Yes	8/34 (23.5)	
<b>Association between dysplasia and HPV</b>		
Pap's smear	No. Infected/No Tested (%)	P-value
Normal	41/174 (23.6)	

Dysplasia	10/26 (38.5)	
Association between p53 mutation and HPV		
p53 mutation	No of mutation per HPV status	P-value
Positive	9/51 (HPV+)	<0.001
Negative	0/149 (HPV-)	
<b>Frequency of multiple hrHPV-genotypes among the participants</b>		
Combination of HPV types	Frequency (%)	
16 + 18	1(11.1%)	
18 + 31	2(22.2%)	
18 + 66	2(22.2%)	
16 + 31	4(44.4%)	

306

307 **Figure 1:** Image of agarose gel electrophoresis after multiplex PCR for HPV genotyping

308 Lanes 7-14 and 18 = HPV 31

309 Lanes 1, 19 and 20 = HPV 16

310 Lanes 5, 6, 15 and 21 = HPV 18

311

312 **Figure 2:** Image of agarose gel electrophoresis with primers targeting approx 600 base pairs of

313 HPV E6/7 genes

314 Lanes 4,5,8,9,13,15,17,22,23,32 and 33 are positive for HPV DNA

315 Lane L is 100 bp ladder

316 Lane NC is the negative control

317

318 **Figure 3:** Image of Agarose gel electrophoresis after Exon 6 mutation (p53) detecting PCR

319 Samples in lanes 1, 2, 10, 11, 12, 13, 14, and 15 all have exon 6 mutations

320

321

### 322 **Interpretation of result**

323 Negative hrHPV genotype was 74.5 percent in this study, while single and multiple hrHPV  
324 genotypes were 21 percent and 4.5 percent, respectively. In addition, 10.7 percent of women had  
325 non-hrHPV-associated mild cervical dysplasia (cervical transformation via an HPV-independent  
326 pathway), while 11.9 percent had hrHPV-associated mild cervical dysplasia (precancerous  
327 changes associated with single hrHPV genotypes). Furthermore, the prevalence of hrHPV-  
328 associated severe cervical dysplasia (precancerous changes caused by a single hrHPV genotype)  
329 was 7.1 percent, while the prevalence of hrHPV-associated mild cervical dysplasia (precancerous  
330 changes due to multiple hrHPV genotypes) was 22.2 percent. The presence of a TP53 gene  
331 mutation was 100% positive for or in concordance with multiple hrHPV genotypes (both with  
332 cervical dysplasia and non-dysplasia). High-risk individuals with a combined p53 mutation and  
333 multiple hrHPV genotypes who had already manifested cervical dysplasia made up 22.2 percent  
334 of this group, while the remaining 77.8 percent had normal cervical tissue architecture, the fate  
335 of which was not known at the time of investigation (Table 2).

336

337

338

339

340

341

342

343

344

345

346

347



348  
349  
350  
351  
352  
353  
354  
355

**Table 2:** Molecular characterizations of hrHPV-genotypes and P53 mutation among the participants

Dysplasia (Pap's smear)			Negative hrHPV			Positive hrHPV					
			Negative hrHPV genotype			Single hrHPV genotype			Multiple hrHPV genotype		
Outcome	Classification	Total cases, n (%)	Tally	Freq. (%)	P53 mutation, n (%)	Tally	Freq. (%)	P53 mutation, n (%)	Tally	Freq. (%)	P53 mutation, n (%)
Positive	HGSIL	3	-	0	0 (0%)		03 (7.1%)	0 (0%)	-	0	0 (0%)
	LGSIL	23		16 (10.7%)	0 (0%)		05 (11.9%)	0 (0%)		02 (22.2%)	2 (100%)
Negative	Inflammatory	19		10 (6.7%)	0 (0%)		08 (19.0%)	0 (0%)		01 (11.1%)	1 (100%)
	Non-reactive	155	   	123 (82.6%)	0 (0%)	             	26 (61.9%)	0 (0%)		06 (66.7%)	6 (100%)
Total	-	200	-	149 (74.5%)	0%	-	42 (21.0%)	0%	-	09 (4.5%)	100%

356 HGSIL: High-grade squamous intraepithelial lesion; LGSIL: Low-grade squamous intraepithelial lesion;

357 HPV: Human papillomavirus; Inflammatory and non-reactive cytologies were considered negative.

358

359 **DISCUSSION**

360 In this study, 200 cervical samples were investigated from consenting women in Osogbo

361 metropolis, southwestern Nigeria, using molecular analyses and cervical cytology. We

362 determined associations between high-risk human papillomavirus (hrHPV) infections and

363 cervical dysplasia, as well as p53 mutation. We also investigated the relationship between these  
364 data and biological and socioeconomic factors.

365 The prevalence of cervical dysplasia (cervical abnormalities) was found to be 13% overall. This  
366 was in accordance with the study of Omole-Ohonsi [25] where 11.6% was reported in a five-year  
367 review of cervical cytology in Abakaliki, Nigeria. Investigating the relationship between cervical  
368 dysplasia and age, which is an established factor for cancer development, the current study  
369 found that people aged 60 and up had the highest frequency of hrHPV infection. Then came  
370 those aged 50 to 59, albeit there was no substantial difference when other age groups were taken  
371 into account, implying that other factors were at play. According to a report, the average age of  
372 cervical cancer diagnosis is 53 years, ranging from 44 to 68 years depending on the region [26].  
373 Cervical cancer incidence increases with age. In other words, cervical cancer is uncommon  
374 between the ages of 20 and 24 years [27], which could explain why pre-cancerous (dysplasia) is  
375 more common as people become older, according to the current study. Pathologically speaking,  
376 cervical dysplasia are known as pre-cancerous cells that are yet to transform into cancerous cells,  
377 but which may have a risk of likelihood later in life, especially if not detected and treated early.  
378 It is worth noting that cervical cancer is more predominant among women groups who have poor  
379 access to screening [28]. Low practice of cervical cancer screening has been reported in Nigeria  
380 [29]. In the present study, it is suggestive that the abnormal positive cases for cytology might  
381 have age-related incidence who probably had not availed themselves for screening  
382 overtime. This is in agreement with a recent study, which suggests that older women from the  
383 poor-resource settings, and coincidentally from the rural areas, have increased risks to develop  
384 cervical cancer and are doubtful to have had screening [30]. This is further attributable to poor  
385 access to health services, ill-equipped health facilities and poor awareness [30].

386 Participants with lowest basic education level showed highest prevalence of HPV infections with  
387 HPV genotypes 16, 18, 31, and 33, respectively, while the least proportion was observed among  
388 those without formal education. This observation suggests that education significantly affected  
389 the prevalence of hrHPV infection among women in Osogbo metropolis. Previous report  
390 established that education has impacts on HPV infection *via* knowledge enrichment and creation  
391 of sexual right awareness [31]. As earlier mentioned, poor awareness has been repeatedly  
392 reported as an independent factor influencing HPV infection [30, 32]. Data from the literature  
393 suggest that educational interventions at high school levels could influence adolescents'  
394 awareness, and offers both preventive knowledge and risk-taking behaviours from contracting  
395 HPV infection [32]. However, some sociodemographic variables, such as religion and  
396 occupation, had no association with the incidence of hrHPV infection, despite the fact that  
397 Muslim women were less infected compared to the Christian counterparts, and civil servants  
398 were slightly more infected. In terms of Islamic rites, vaginal cleansing may have a positive  
399 impact on HPV infection among the Muslim participants. Furthermore, a slightly higher  
400 proportion of participants had normal menstrual periods, despite having more hrHPV infections.  
401 Our findings suggest that having HPV-infection does not affect menstrual cycle. Unfortunately,  
402 the scope of our study did not take into account the menstrual phase. Although, the available  
403 information is still contradictory and inconsistent, according to one study, HPV detection is  
404 unrelated to menstrual cycle [33]. On the other hand, emerging evidence suggest that the  
405 menstrual cycle phase may influence the HPV-DNA detection [34]. The current study, however,  
406 highlights the need for additional research on the impact of hormones on papillomavirus  
407 genotype, pathogenicity, and epithelial tropism.

408 More so, the variations of hrHPV detection was cross-examined with the prevalence. The  
409 cumulative percentage of HPV infection was 25.5%, and the common oncogenic genotypes  
410 (often associated with genital cancers) were HPV16, HPV18, HPV31, HPV33, and HPV39, with  
411 HPV31 being the most predominant genotype. Various studies show inconsistent prevalence  
412 rates of HPV across the globe, and continental and local regions, using various methods of  
413 detection. In Ibadan, a neighbouring city in Nigeria, Neto et al. [35] recently reported 17.3%  
414 HPV prevalence using DNA consensus primer to identify fifteen different HPV genotypes,  
415 where only HPV-16, 18, 31, and 33 oncogenic subtypes are in accordance with the finding of  
416 the present study. All the same, the most predominant HPV genotype in the present study,  
417 HPV31, is in concordance with the outcome of Neto et al. [35]. Again, in Maiduguri, a Muslim  
418 dominated city in northern Nigeria, Kabir et al. [36] reported 69.8% prevalence rate of HPV  
419 using DNA detection method. Also, a robust review study of several low-resource countries by  
420 Nweke et al. [37] shows that sub-Saharan African has high prevalence rates of HPV infection  
421 predominated with three high-risk genotypes, HPV-16, 18, and 45, two of which were also  
422 detected in the present study. According to their age in relation with HPV prevalence rate, the  
423 oldest age range (60years and above) had highest prevalence of HPV infections followed by the  
424 second uppermost age range (50-59year). Report shows that older postmenopausal age women  
425 face challenges of persistent infection with HPV [38].

426 In relating sexual activities with the rate of contracting HPV, excluding other possible factors,  
427 this study further correlated coital frequency with HPV prevalence. Intriguingly, the women that  
428 had monthly regular coitus reported highest prevalence rate of 29.8%, while the weekly coitus  
429 had the least, 17.8% (Table 1). Of particular interest, the women with monthly coitus showed  
430 positivity for HPV31, HPV16, HPV18, HPV33 and HPV66 in that order of preponderance (with

431 HPV 18 and 33 indicating equal rate and HPV66 the lowest). However, no statistical strength to  
432 show that regular sexual intercourse on monthly basis influence the disease in women who had  
433 the highest prevalence of HPV types 16, 18, 31 and 33 infections. Even though, on most  
434 occasions, HPV infection occurs through sexual intercourse [39, 40], albeit, HPV transmission is  
435 also possible by non-penetrative genital contacts and transmission *via* non-sexual routes such as  
436 from mother to baby during late prenatal and early post-natal periods, as well as through hand to  
437 genital contact [41] that might impact beyond coital frequency. It was therefore not surprising  
438 that the group with weekly coital frequency had a lower rate of hrHPV infection than monthly  
439 group, and that the group with sexual abstinence had higher hrHPV-infection rate than those with  
440 frequent intercourse. As a result, it was believed that other factors likely contributed to hrHPV  
441 infection in the current study and that it was unlikely that sexual activity had a significant  
442 impact.

443 A study of Chinese population in a rural area found oncogenic HPV types, especially for HPV16,  
444 31, 33, 52, and 58, with HPV16 (19.1%) and HPV52 (16.5%) as the most preponderance and are  
445 often attributed to cervical intraepithelial neoplasia grade I and II (CINI&II) [42]. Apart from  
446 abnormal cytology report, a different but systematic review study of several reports from twenty  
447 three African countries reports that 4.4% and 2.8% of women with normal cytology have  
448 hrHPV16 and 18, respectively [43]. HPV16 and HPV18 are the most common HPVs detected  
449 worldwide, including many African countries, nonetheless, there are occasions where HPV-31  
450 has been reported [35] similar with the present study.

451 Although HPV 16 has been widely reported as the most preponderant genotype, however,  
452 attributable to geographical variation, some studies report that HPV16 may not be the most  
453 common HPV genotype in some settings. Similarly, different HPV-genotypes have different

454 clinical implications. Study shows that HPV 52 is the most common type in CIN II across all age  
455 categories [44], and has the highest preponderance as indicated in another study conducted in  
456 Zhejiang Province [45]. HPV 51, 52, and 31 are also more common in precancerous lesions than  
457 in invasive cervical cancer, despite the fact that HPV 16, 18, and 45 are more frequent in  
458 invasive cervical cancer than in any other grades of cervical malignancy [46].  
459 Besides, many studies from Africa have observed multiple HPV infections [47]. However, those  
460 studies that identified multiple HPV types suggested the possibility of synergism and additivity,  
461 as well as an association with persistent infection and a higher risk of disease progression [48].  
462 On the other hand, Salazar *et al.* [49] have shown that no significant difference occurs between  
463 single and multiple HPV infections. In this study, both HPV-associated and non-HPV associated  
464 cervical dysplasia (mild and severe precancerous changes) were observed (Table 2). Similarly,  
465 both single and multiple hrHPV genotypes were equally observed. Interestingly, all the cases  
466 with multiple hrHPV genotypes showed p53 inactivation with substantial portion manifesting  
467 low-grade squamous intraepithelial lesion (LGSIL). On the other hand, none among the  
468 participants with single HPV genotypes showed p53 dysfunction, albeit, some proportions  
469 already manifesting both high-grade squamous intraepithelial lesion (HGSIL) and LGSIL (Table  
470 2). Meanwhile, dysfunction of p53 has been reported in several malignant tumours [50]. In  
471 particular, during cervical cancer progression, p53 inactivation occurs by degradation through  
472 the HPV oncoprotein E6 and E6-associated protein (E6AP) complex [51]. Kim *et al.* [52]  
473 demonstrated that TP53 gene mutations are infrequent in primary cervical cancer or  
474 precancerous lesions, and that HPV infection and TP53 gene mutation have no mutual  
475 relationship. On the other hand, our results of multiple hrHPV genotypes and P53 mutation  
476 occurring coincidentally, despite the lack of a discernible causal relationship, could indicate

477 previously unreported molecular interplay in the etiology of cervical cancer - what we termed  
478 "synchronicity".

479 Moreover, both hrHPV genotypes and P53 mutation are established risk factors for cervical  
480 cancer. Furthermore, despite the fact that the vast majority of this group (with many hrHPV  
481 genotypes) was still classed as normal cytology, there was a substantial number of aberrant  
482 cervical architecture (Table 2). Cervical cancer is a slow-growing malignancy. Because aberrant  
483 alterations in the cervix might take years or even decades to develop into invasive cancer cells,  
484 thus it is still unclear if the currently normal cytology will ultimately lead to a full-blown  
485 carcinoma.

486 Even though the majority of the subjects (74.5%) tested negative for the hrHPV genotype and  
487 without p53 mutation, a significant proportion of this group revealed a squamous intraepithelial  
488 lesion, non-HPV-associated dysplasia, the cause of which was unknown. This shows that  
489 cervical abnormalities were mediated by etiologic factors other than the p53 mutation and  
490 hrHPV-infection. In other words, there are other independent mechanisms exclusive of p53  
491 inactivation, which might implicate development of cervical precancerous lesions as well as  
492 cervical cancer.

493 Literature shows that multiple genetic alterations accumulate in human cancers, which may  
494 involve inactivation of tumour suppressor genes [53] such as p53, oncogene activation, as well as  
495 loss of distinct chromosomal regions. However, base sequence mutation in p53 tumour  
496 suppressor gene occurs most frequently [54]. Albeit, in association with etiology of cervical  
497 cancer p53 gene mutations rarely occurs but only in 2-11% [52]. In the present study, p53  
498 mutation was not reported among the participants either with single hrHPV genotypes or with  
499 negative for hrHPV infection; nonetheless, all participants with multiple HPV genotypes had p53

500 inactivation. On the contrary, this report also indicated that non-HPV-associated mild cervical  
501 dysplasia was still a striking figure, 10.7 % (table 2). In addition, both HGSIL and LGSIL do not  
502 necessary result in cancer if treatment is instituted aggressively. However, in the aftermath of  
503 cervical cancer development, our findings indicated that the idea that hrHPV causes about 99.7%  
504 of cancer as repeatedly reported [3, 55] or that p53 is exclusively involved in the molecular  
505 mechanism requires further investigation. As a result, the stakeholders should be aware of the  
506 possibility of a surge of millions of non-HPV-associated cervical cancer cases that might not  
507 benefit from vaccines, even though the current vaccination strategies are thought to eradicate  
508 cervical cancer in the near future.

## 509 510 **CONCLUSION**

511 The p53 mutation and hrHPV infections were thought to be independent risk factors and  
512 determinants of cervical cancer development. Our findings, however, showed that the p53  
513 mutation coexists in host tissue infected with multiple hrHPV genotypes. This suggests that  
514 multiple hrHPV infections and p53 susceptibility may interplay in a way that increases the risk  
515 of cervical cancer. However, in a single hrHPV genotype, p53 gene mutation was independent of  
516 HPV-associated cervical architectural abnormalities, though other mechanistic drivers attributed  
517 to p53 dysfunction by E6 and E7 remained plausible. Furthermore, non-HPV-associated cervical  
518 dysplasia was found in 10.7% of the participants in the current study while 99.7% of HPV-  
519 induced cervical cancer has been repeatedly reported in the literature. Our findings also implied  
520 that the PCR employing HPV DNA test is more sensitive than the Pap's smear in detecting  
521 hrHPV at an early stage, even before cervical dysplasia develops. As a result, the HPV DNA test  
522 should be considered a baseline for early detection. Meanwhile, HPV infection is  
523 largely implicated in the pathogenesis of cervical cancer prompting the development of HPV



524 vaccines. Therefore, putting these together, stakeholders should be aware of the possibility of an  
525 increase in the number of non-HPV-associated cervical cancer cases in less developed countries  
526 where efficient HPV screening methods are lacking.

527

528

### 529 **Limitation**

530 The seeming number of participants who declined to take part was significant. The cultural and  
531 religious beliefs impacted the sample size significantly, considering the types of data required.

532 The majority of the participants found it difficult to declare their sexual intercourse statuses,  
533 resulting in a large number of data gaps and thus excluded from the study. The reasons were  
534 considered to be in conjunction with unaccustomed use to declaring any sexual connexion  
535 openly or in any related ways, whether before marriage or out of the marital household in respect  
536 to Yoruba culture, and to some extent religiously.

### 537 **Acknowledgments**

538 Prof. I. O. Ajayi of the University of Benin's Department of Physiology deserves special thanks  
539 for his suggestions and advise on this project. We also acknowledge Dr. (Mrs) Faneye of the  
540 University of Ibadan, Department of Virology and Mrs. B. Farinloye of the University College  
541 Hospital, Pathology Department for their expertise and technical assistance during the analyses.  
542 Our gratitude goes to the staff members, from the Head of Department, Prof. (Mrs.) E.O. Osime  
543 to other members most particularly Profs. M.A.Emokpae, I.N. Ibeh, F.E.Osaronsarje, H.B.  
544 Osadolor, M.A. Olungborva, E.O. Osime, E.B. Odigie for imparting this work positively.

545

### 546 **Author Contributions**

547 Conceptualization: Frederick Akinbo, Musiliu Oyenike.

548 Data curation: Musiliu Oyenike.

549 Literature search: Musiliu Oyenike, Kamoru Adedokun  
550 Formal analysis: Musiliu Oyenike.  
551 Investigation: Musiliu Oyenike.  
552 Methodology: Frederick Akinbo, Musiliu Oyenike, Kamoru Adedokun.  
553 Statistical analyses: Hammed Ojokuku, Kamoru Adedokun.  
554 Data interpretation: Kamoru Adedokun  
555 Project administration: Frederick Akinbo, Musiliu Oyenike  
556 Resources: Musiliu Oyenike.  
557 Supervision: Frederick Akinbo.  
558 Writing – original draft: Kamoru Adedokun.  
559 Writing – review & editing: Kamoru Adedokun, Musiliu. Oyenike, Hammed Ojokuku, Sikiru  
560 Imodoye, Lukman Yunus, Ismaila Lasisi, and Abdulahi Jimoh.  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574

575

576

577

578

579

580 **REFERENCES**

- 581 1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable  
582 to infections in 2018: a worldwide incidence analysis. *Lancet Glob Health*. 2020;8(2):e180-  
583 e190. doi: 10.1016/S2214-109X(19)30488-7.
- 584 2. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-  
585 cycle of human papillomaviruses. *Vaccine*. 2012;30 Suppl 5:F55-70. doi:  
586 10.1016/j.vaccine.2012.06.083.
- 587 3. Okunade KS. Human papillomavirus and cervical cancer. *J Obstet Gynaecol*. 2019:1-7. doi:  
588 10.1080/01443615.2019.1674261.
- 589 4. Globocan. Cancers Fact Sheets, 2020. [homepage on the internet] International Agency for  
590 Research on Cancer (IARC); 2020 [cited 2022 Mar 26].  
591 <https://gco.iarc.fr/today/data/factsheets/populations/566-nigeria-fact-sheets.pdf>
- 592 5. American Cancer Society. 2018. [cited 2022 Mar 26].  
593 <https://www.cancer.org/content/dam/CRC/PDF/Public/8600.00.pdf>.
- 594 6. Herrero AB, Rojas EA, Misiewicz-Krzeminska I, Krzeminski P, Gutiérrez NC. Molecular  
595 Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. *Int J Mol*  
596 *Sci*. 2016;17(12):2003. doi: 10.3390/ijms17122003.

- 597 7. Hashimoto N, Nagano H, Tanaka T. The role of tumor suppressor p53 in metabolism and  
598 energy regulation, and its implication in cancer and lifestyle-related diseases. *Endocr J*.  
599 2019;66(6):485-496. doi: 10.1507/endocrj.EJ18-0565.
- 600 8. Nakamura M, Obata T, Daikoku T, Fujiwara H. The Association and Significance of p53 in  
601 Gynecologic Cancers: The Potential of Targeted Therapy. *Int J Mol Sci*. 2019;20(21):5482.  
602 doi: 10.3390/ijms20215482.
- 603 9. Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key Molecular Events in Cervical  
604 Cancer Development. *Medicina (Kaunas)*. 2019;55(7):384. doi: 10.3390/medicina55070384.
- 605 10. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma  
606 cells by small molecules. *Proc Natl Acad Sci U S A*. 2000;97(15):8501-6. doi:  
607 10.1073/pnas.97.15.8501.
- 608 11. Tornesello ML, Buonaguro L, Buonaguro FM. Mutations of the TP53 gene in  
609 adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. *Gynecol*  
610 *Oncol*. 2013;128(3):442-8. doi: 10.1016/j.ygyno.2012.11.017.
- 611 12. Gbadegesin MA, Omotoso OE, Oluwasola TAO, Okolo CA, Soremekun O, Ogun GO, et  
612 al. Mutational analysis of p53 gene in cervical cancer and useful polymorphic variants in  
613 exons 3 and 4. *Egypt J Med Hum Genet*. 2021;22:23. [https://doi.org/10.1186/s43042-021-](https://doi.org/10.1186/s43042-021-00144-1)  
614 00144-1.
- 615 13. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism.  
616 *Cancer Lett*. 2015;28;356(2 Pt A):197-203. doi: 10.1016/j.canlet.2013.12.025.
- 617 14. Jiboye AD. Significance of house-type as a determinant of residential quality in Osogbo,  
618 Southwest Nigeria. *Front. Archit. Res.* 2014;3(1):20-27.  
619 <https://doi.org/10.1016/j.foar.2013.11.006>.

- 620 15. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical  
621 studies. *Gastroenterology and Hepatology from Bed to Bench*. 2013;6(1):14–17.
- 622 16. Kavatkar AN, Nagwamshi CA, Dabaks M. Study of a manual method of liquid based  
623 cervical cytology. *Indian J. Pathol. Microbiol.* 2008;59:190-194.
- 624 17. Dhananjaya C, Kumari MK. Comparison of manual Liquid Based Cytology and  
625 Conventional Pap Smear in Cervical Cancer Screening. *Natl. lab. med.* 2017;6(2):32-37.
- 626 18. Yakub MM, Fowotade A, Anaedobe CG, Manga MM, Bakare RA, Abimiku BA. Human  
627 papillomavirus correlates of high grade cervical dysplasia among HIV-Infected women at a  
628 major treatment centre in Nigeria: a cross-sectional study. *Pan Afr Med J.* 2019;33:125. doi:  
629 10.11604/pamj.2019.33.125.17589.
- 630 19. Avwioro OG. Text book of Histochemistry and tissue pathology, principle and techniques.  
631 2002. 2<sup>nd</sup> edition. University Press, Delta State University, Abraka, Nigeria.
- 632 20. Nayar R, Wilbur DC. (Eds.) 2015. The Bethesda System for Reporting Cervical  
633 Cytology. doi:10.1007/978-3-319-11074-5.
- 634 21. Romero-Pastrana F. Detection and Typing of Human Papilloma Virus by Multiplex PCR  
635 with Type-Specific Primers. *ISRN Microbiology.* 2012;1–5.
- 636 22. Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, et al. Detection and typing  
637 of human papillomavirus by E6 nested multiplex PCR. *J Clin Microbiol.* 2004;42(7):3176-  
638 84. doi: 10.1128/JCM.42.7.3176-3184.2004.
- 639 23. Andersson CR, Isaksson A, Gustafsson MG. Bayesian detection of periodic mRNA time  
640 profiles without use of training examples. *BMC Bioinformatics.* 2006;7:63. doi:  
641 10.1186/1471-2105-7-63.

- 642 24. do Horto dos Santos Oliveira L, Rodrigues Ede V, de Salles Lopes AP, Fernandez Ade P,  
643 Cavalcanti SM. HPV 16 detection in cervical lesions, physical state of viral DNA and  
644 changes in p53 gene. Sao Paulo Med J. 2003;121(2):67-71. doi: 10.1590/s1516-  
645 31802003000200007.
- 646 25. Omole-Ohonsi A, Aiyedun TA, Umoru JU. Diagnostic accuracy of VIA compared to Pap  
647 smear cytology in detecting premalignant lesions of the cervix. Afr. J. Med. Health Sci.  
648 2013;12:25–30.
- 649 26. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of  
650 incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob  
651 Health. 2020;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Erratum in: Lancet  
652 Glob Health. 2022;10(1):e41.
- 653 27. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical  
654 cancer screening for individuals at average risk: 2020 guideline update from the American  
655 Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. doi: 10.3322/caac.21628.
- 656 28. Eshete M, Abdulwuhab Atta M, Yeshita HY. Cervical Cancer Screening Acceptance among  
657 Women in Dabat District, Northwest Ethiopia, 2017: An Institution-Based Cross-Sectional  
658 Study. Obstet Gynecol Int. 2020;2020:2805936. doi: 10.1155/2020/2805936.
- 659 29. Ahmed SA, Ayuba HU, Maiangwa A, Vakkai VI, Dashe DR, Joel R, et al. (2013).  
660 Prevalence of squamous intraepithelial lesions of the cervix in Jalingo, Nigeria. Afr. J. Cell.  
661 Pathol. 2013;1(1):19-22.
- 662 30. Ndejjo R, Mukama T, Musabyimana A, Musoke D. Uptake of Cervical Cancer Screening  
663 and Associated Factors among Women in Rural Uganda: A Cross Sectional Study. PLoS  
664 One. 2016;11(2):e0149696. doi: 10.1371/journal.pone.0149696.


- 665 31. Kim HW, Park S, Ahn HY, Park EJ. The effects of an HPV education program by gender  
666 among Korean university students. *Nurse Educ Today*. 2015;35(4):562-7. doi:  
667 10.1016/j.nedt.2014.12.014.
- 668 32. Grandahl M, Rosenblad A, Stenhammar C, Tydén T, Westerling R, Larsson M, et al.  
669 School-based intervention for the prevention of HPV among adolescents: a cluster  
670 randomised controlled study. *BMJ Open*. 2016;6(1):e009875. doi: 10.1136/bmjopen-2015-  
671 009875.
- 672 33. Tota JE, Ramanakumar AV, Mahmud SM, Trevisan A, Villa LL, Franco EL; Ludwig-  
673 McGill Cohort Study Group. Cervical human papillomavirus detection is not affected by  
674 menstrual phase. *Sex Transm Infect*. 2013;89(3):202-6. doi: 10.1136/sextrans-2012-050610.
- 675 34. Liu SH, Brotman RM, Zenilman JM, Gravitt PE, Cummings DA. Menstrual cycle and  
676 detectable human papillomavirus in reproductive-age women: a time series study. *J Infect*  
677 *Dis*. 2013;208(9):1404-15. doi: 10.1093/infdis/jit337.
- 678 35. Nejo YT, Olaleye DO, Odaibo GN. Molecular characterisation of genital human  
679 papillomavirus among women in Southwestern, Nigeria. *Plos one*. 2019;14(11):e0224748.  
680 doi: 10.1371/journal.pone.0224748.
- 681 36. Kabir A, Bukar M, Nggada HA, Rann HB, Gidado A, Musa AB. Prevalence of human  
682 papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. *Pan Afr Med J*.  
683 2019;33:284. doi: 10.11604/pamj.2019.33.284.18338.
- 684 37. Nweke MC, Okolo CA, Daous Y, Esan OA. Challenges of Human Papillomavirus Infection  
685 and Associated Diseases in Low-Resource Countries. *Arch. pathol. lab. med*. 2018;142(6):  
686 696–699.

- 687 38. Smith EM, Johnson SR, Ritchie JM, Feddersen D, Wang D, Turek LP, et al. Persistent HPV  
688 infection in postmenopausal age women. *Int J Gynaecol Obstet.* 2004;87(2):131-7. doi:  
689 10.1016/j.ijgo.2004.07.013.
- 690 39. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. *Aust N Z J*  
691 *Obstet Gynaecol.* 2011;51(2):103-8. doi: 10.1111/j.1479-828X.2010.01269.x.
- 692 40. Pamnani SJ, Sudenga SL, Rollison DE, Ingles DJ, Abrahamsen M, Villa LL, et al.  
693 Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6,  
694 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. *J*  
695 *Infect Dis.* 2018;218(8):1219-1227. doi: 10.1093/infdis/jiy300.
- 696 41. Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, Stanley MA. Presence of  
697 antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old  
698 schoolgirls. *J Med Virol.* 1998;56(3):210-6.
- 699 42. Zhao XL, Hu SY, Zhang Q, Dong L, Feng RM, Han R, et al. High-risk human  
700 papillomavirus genotype distribution and attribution to cervical cancer and precancerous  
701 lesions in a rural Chinese population. *J Gynecol Oncol.* 2017;28(4):e30. doi:  
702 10.3802/jgo.2017.28.e30.
- 703 43. Ogembo RK, Gona PN, Seymour AJ, Park HS, Bain PA, Maranda L, et al. Prevalence of  
704 human papillomavirus genotypes among African women with normal cervical cytology and  
705 neoplasia: a systematic review and meta-analysis. *PLoS One.* 2015;10(4):e0122488. doi:  
706 10.1371/journal.pone.0122488.
- 707 44. So KA, Lee IH, Lee KH, Hong SR, Kim YJ, Seo HH, et al. Human papillomavirus  
708 genotype-specific risk in cervical carcinogenesis. *J Gynecol Oncol.* 2019;30(4):e52. doi:  
709 10.3802/jgo.2019.30.e52.




- 710 45. Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution  
711 of HPV genotypes in women from Zhejiang Province, 2016-2020. *Virology*. 2021;18(1):208.  
712 doi: 10.1186/s12985-021-01676-z.
- 713 46. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al.  
714 Differences in human papillomavirus type distribution in high-grade cervical intraepithelial  
715 neoplasia and invasive cervical cancer in Europe. *Int J Cancer*. 2013;132:854–867.
- 716 47. Adler D, Laher F, Wallace M, Grzesik K, Jaspan H, Bekker LG, et al. High Rate of Multiple  
717 Concurrent Human Papillomavirus Infections among HIV-Uninfected South African  
718 Adolescents. *J Immunol Tech Infect Dis*. 2013;2(1):1000106.
- 719 48. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human  
720 papillomavirus infections with multiple types and risk of cervical neoplasia. *Cancer*  
721 *Epidemiol Biomarkers Prev*. 2006;15(7): 1274–80.
- 722 49. Salazar KL, Zhou HS, Xu J, Peterson LE, Schwartz MR, Mody DR et al. Multiple Human  
723 Papilloma Virus Infections and Their Impact on the Development of High-Risk Cervical  
724 Lesions. *Acta Cytologica*. 2015;59(5):391-398. <https://doi.org/10.1159/000442512>.
- 725 50. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, et al.  
726 Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. *Blood*.  
727 2012;119(16):3668-83. doi: 10.1182/blood-2011-11-366062.
- 728 51. Poirson J, Biquand E, Straub ML, Cassonnet P, Nominé Y, Jones L, et al. Mapping the  
729 interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system. *FEBS J*.  
730 2017;284(19):3171-3201. doi: 10.1111/febs.14193.


- 731 52. Kim JW, Cho YH, Lee CG, Kim JH, Kim HK, Kim EJ, et al. Human papillomavirus  
732 infection and TP53 gene mutation in primary cervical carcinoma. *Acta Oncol.*  
733 1997;36(3):295-300. doi: 10.3109/02841869709001266.
- 734 53. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene:  
735 Important Milestones at the Various Steps of Tumorigenesis. *Genes Cancer.* 2011;2(4):466-  
736 74. doi: 10.1177/1947601911408889.
- 737 54. Revollo J, Petibone DM, McKinzie P, Knox B, Morris SM, Ning B, et al. Whole genome  
738 and normalized mRNA sequencing reveal genetic status of TK6, WTK1, and NH32 human  
739 B-lymphoblastoid cell lines. *Mutat Res Genet Toxicol Environ Mutagen.* 2016;795:60-9.  
740 doi: 10.1016/j.mrgentox.2015.11.006.
- 741 55. Lockwood-Rayermann S, McIntyre SJ. Understanding HPV disease and prevention: a guide  
742 for school nurses. *J Sch Nurs.* 2009;25(4):261-9. doi: 10.1177/1059840509333787.



medRxiv preprint doi: <https://doi.org/10.1101/2022.06.28.22277026>; this version posted June 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Figure



Figure